First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome

Elisabetta Garavaglia,1 Cinzia Sala,2 Manuela Busato,1 Gilberto Bellia,3 Nadia Tamburlin,1 Alberto Massirone1 1Agorà, Italian Scientific Society of Aesthetic Medicine, Milan, Italy; 2Private Practice, Milan, Italy; 3Medical Affair, IBSA Farmaceutici, Italia Srl, Lodi, ItalyCorrespondence:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Garavaglia E, Sala C, Busato M, Bellia G, Tamburlin N, Massirone A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	hyaluronic acid bio-stimulation vulvovaginal atrophy genito-urinary syndrome of menopause hyaluronic acids injection menopause hyaluronan hybrid cooperative complexes Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/80aec5dccdcc4ef4858c4dc9e1e45198
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:80aec5dccdcc4ef4858c4dc9e1e45198
record_format	dspace
spelling	oai:doaj.org-article:80aec5dccdcc4ef4858c4dc9e1e451982021-12-02T15:16:27ZFirst Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome1179-1470https://doaj.org/article/80aec5dccdcc4ef4858c4dc9e1e451982020-12-01T00:00:00Zhttps://www.dovepress.com/first-use-of-thermal-stabilized-hyaluronic-acid-injection-in-one-year--peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470Elisabetta Garavaglia,1 Cinzia Sala,2 Manuela Busato,1 Gilberto Bellia,3 Nadia Tamburlin,1 Alberto Massirone1 1Agorà, Italian Scientific Society of Aesthetic Medicine, Milan, Italy; 2Private Practice, Milan, Italy; 3Medical Affair, IBSA Farmaceutici, Italia Srl, Lodi, ItalyCorrespondence: Elisabetta GaravagliaAgorà, Italian Scientific Society of Aesthetic Medicine, Piazza Caiazzo 1, Milan 20124, ItalyTel +39 3382731072Email Garavaglia.Elisabetta@hsr.itObjective: Evaluation of the impact of hyaluronan hybrid cooperative complex (HCC) injections in premenopausal and postmenopausal Italian women affected by vulvar-vaginal atrophy (VVA), one of the symptoms of genitourinary syndrome (GS), on self-reported quality-of-life, vaginal symptoms, and sexual activity, as well as treatment side-effects.Methods: We surveyed a sample of 26 women affected by VVA with follow-up at 6 and 12 months. Deep intradermal injections of HCC were delivered at 1-month intervals. Evaluation of the treatment impacting the VVA patients was assessed by three international validated questionnaires (Visual Analogic Scale, VAS; health-related quality-of-life test, SF12; Female Sexual Function Index, FSFI). The statistically significant differences between pre- and after-treatment responses have been assessed by Wilcoxon signed-rank test and repeated measures ANOVA test.Results: At 6– 12-month follow-up, general quality-of-life (SF12) did not show any significant improvement. On the contrary, VVA patients showed significant improvements of genital symptoms (VAS) and sexual function (FSFI). Global FSFI score increased by 58% and evidenced important satisfaction (P≤ 0.05).Conclusion: Vestibular HCC injection is an office, safe, fast, not expensive, and reproducible procedure effective in vulvar-vaginal atrophy. This study can be used as a pilot for future trials.Keywords: hyaluronic acid, bio-stimulation, vulvovaginal atrophy, genito-urinary syndrome of menopause, hyaluronic acids injection, menopause, hyaluronan hybrid cooperative complexesGaravaglia ESala CBusato MBellia GTamburlin NMassirone ADove Medical Pressarticlehyaluronic acidbio-stimulationvulvovaginal atrophygenito-urinary syndrome of menopausehyaluronic acids injectionmenopausehyaluronan hybrid cooperative complexesMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol Volume 13, Pp 399-410 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	hyaluronic acid bio-stimulation vulvovaginal atrophy genito-urinary syndrome of menopause hyaluronic acids injection menopause hyaluronan hybrid cooperative complexes Medical technology R855-855.5
spellingShingle	hyaluronic acid bio-stimulation vulvovaginal atrophy genito-urinary syndrome of menopause hyaluronic acids injection menopause hyaluronan hybrid cooperative complexes Medical technology R855-855.5 Garavaglia E Sala C Busato M Bellia G Tamburlin N Massirone A First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome
description	Elisabetta Garavaglia,1 Cinzia Sala,2 Manuela Busato,1 Gilberto Bellia,3 Nadia Tamburlin,1 Alberto Massirone1 1Agorà, Italian Scientific Society of Aesthetic Medicine, Milan, Italy; 2Private Practice, Milan, Italy; 3Medical Affair, IBSA Farmaceutici, Italia Srl, Lodi, ItalyCorrespondence: Elisabetta GaravagliaAgorà, Italian Scientific Society of Aesthetic Medicine, Piazza Caiazzo 1, Milan 20124, ItalyTel +39 3382731072Email Garavaglia.Elisabetta@hsr.itObjective: Evaluation of the impact of hyaluronan hybrid cooperative complex (HCC) injections in premenopausal and postmenopausal Italian women affected by vulvar-vaginal atrophy (VVA), one of the symptoms of genitourinary syndrome (GS), on self-reported quality-of-life, vaginal symptoms, and sexual activity, as well as treatment side-effects.Methods: We surveyed a sample of 26 women affected by VVA with follow-up at 6 and 12 months. Deep intradermal injections of HCC were delivered at 1-month intervals. Evaluation of the treatment impacting the VVA patients was assessed by three international validated questionnaires (Visual Analogic Scale, VAS; health-related quality-of-life test, SF12; Female Sexual Function Index, FSFI). The statistically significant differences between pre- and after-treatment responses have been assessed by Wilcoxon signed-rank test and repeated measures ANOVA test.Results: At 6– 12-month follow-up, general quality-of-life (SF12) did not show any significant improvement. On the contrary, VVA patients showed significant improvements of genital symptoms (VAS) and sexual function (FSFI). Global FSFI score increased by 58% and evidenced important satisfaction (P≤ 0.05).Conclusion: Vestibular HCC injection is an office, safe, fast, not expensive, and reproducible procedure effective in vulvar-vaginal atrophy. This study can be used as a pilot for future trials.Keywords: hyaluronic acid, bio-stimulation, vulvovaginal atrophy, genito-urinary syndrome of menopause, hyaluronic acids injection, menopause, hyaluronan hybrid cooperative complexes
format	article
author	Garavaglia E Sala C Busato M Bellia G Tamburlin N Massirone A
author_facet	Garavaglia E Sala C Busato M Bellia G Tamburlin N Massirone A
author_sort	Garavaglia E
title	First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome
title_short	First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome
title_full	First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome
title_fullStr	First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome
title_full_unstemmed	First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome
title_sort	first use of thermal stabilized hyaluronic acid injection in one-year follow-up patients with genitourinary syndrome
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/80aec5dccdcc4ef4858c4dc9e1e45198
work_keys_str_mv	AT garavagliae firstuseofthermalstabilizedhyaluronicacidinjectioninoneyearfollowuppatientswithgenitourinarysyndrome AT salac firstuseofthermalstabilizedhyaluronicacidinjectioninoneyearfollowuppatientswithgenitourinarysyndrome AT busatom firstuseofthermalstabilizedhyaluronicacidinjectioninoneyearfollowuppatientswithgenitourinarysyndrome AT belliag firstuseofthermalstabilizedhyaluronicacidinjectioninoneyearfollowuppatientswithgenitourinarysyndrome AT tamburlinn firstuseofthermalstabilizedhyaluronicacidinjectioninoneyearfollowuppatientswithgenitourinarysyndrome AT massironea firstuseofthermalstabilizedhyaluronicacidinjectioninoneyearfollowuppatientswithgenitourinarysyndrome
_version_	1718387455510446080

First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome

Ejemplares similares